Enanta Pharmaceuticals Announces New Data Presentations on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2...
September 27 2017 - 4:14PM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced new data presentations on EDP-305, Enanta’s lead FXR
agonist being developed for non-alcoholic steatohepatitis (NASH)
and primary biliary cholangitis (PBC), have been accepted for
presentation at The Liver Meeting® 2017, the Annual Meeting of the
American Association for the Study of Liver Diseases (AASLD) taking
place October 20-24, 2017 in Washington, D.C.
Additionally, Enanta has submitted an abstract to AASLD for
consideration of Late Breaking data from its Phase 1 clinical study
of EDP-305, including pharmacokinetic and biomarker data, and is
planning to have this data announced either in a Late Breaking
presentation or poster at The Liver Meeting or as otherwise
presented by Enanta.
According to AASLD, the following abstract titles can now be
viewed at the AASLD website at
https://www.aasld.org/events-professional-development/liver-meeting/program-0/preliminary-program,
and the full abstracts will be available in print and posted online
on October 1, 2017.
Friday, October 20Poster Presentation, 8:00 am - 5:30 pm
ETSession: Basic Fibrosis Research and Stellate Cell Biology#367 –
“A novel FXR agonist EDP-305 potently suppresses hepatic stellate
cell activation and hepatic fibrosis in chronic mouse models of
biliary and metabolic liver disease”
Monday, October 23Oral Presentation, 8:00 - 9:30 am
ETParallel Session 23: Steatosis and Steatohepatitis: Experimental
I#162 – “Significant anti-fibrotic efficacy of EDP-305, a highly
potent and selective farnesoid X receptor (FXR) agonist, in a rat
model of thioacetamide-induced liver fibrosis and cirrhosis”
Monday, October 23Poster Presentation, 8:00 am - 5:30 pm
ETSession: Steatohepatitis: Experimental#1988 – “EDP-305 favorably
regulates lipoprotein mechanism in vitro”
About EnantaEnanta Pharmaceuticals has used its robust,
chemistry-driven approach and drug discovery capabilities to become
a leader in the discovery of small molecule drugs for the treatment
of viral infections and liver diseases. Two protease inhibitors,
paritaprevir and glecaprevir, discovered and developed through
Enanta’s collaboration with AbbVie, have now been approved in
jurisdictions around the world as part of AbbVie’s direct-acting
antiviral (DAA) regimens for the treatment of hepatitis C virus
(HCV) infection, including the U.S. marketed regimens MAVYRET™
(glecaprevir/pibrentasvir) and VIEKIRA PAK®
(paritaprevir/ritonavir/ombitasvir/dasabuvir).
Royalties and milestone payments from the AbbVie collaboration
are helping to fund Enanta’s research and development efforts,
which are currently focused on the following disease targets:
non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis
(PBC), respiratory syncytial virus (RSV) and hepatitis B virus
(HBV). Please visit www.enanta.com for more information.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170927006300/en/
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.comorMedia ContactMacDougall
Biomedical CommunicationsKari Watson,
781-235-3060kwatson@macbiocom.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024